Hospital compliance with performance measures and 30-day outcomes in patients with heart failure

American Heart Journal

Volumn 164, Issue 1, 2012, Pages 80-86

  Schopfer, David W ^a   Whooley, Mary A ^b,c   Stamos, Thomas D ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DATA BASE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT COUNSELING; PRIORITY JOURNAL; SMOKING CESSATION; SOCIOECONOMICS; UNITED STATES;

ADULT; GUIDELINE ADHERENCE; HEART FAILURE; HOSPITALS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); TIME FACTORS; UNITED STATES;

EID: 84863718611     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.04.017     Document Type: Article

References (31)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209.
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123:933-44.
3. Bonow RO, Bennett S, Casey Jr DE, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop heart failure clinical performance measures): endorsed by the Heart Failure Society of America. Circulation 2005;112:1853-87. (Pubitemid 41368160)
4. Fonarow GC, Peterson ED. Heart failure performance measures and outcomes: real or illusory gains. JAMA 2009;302:792-4.
5. Hospital Compare. In. Washington, DC: U.S. Department of Health & Human Services.
6. The Dartmouth Atlas of Healthcare. In. Dartmouth, NH.
7. Kfoury AG, French TK, Horne BD, et al. Incremental survival benefit with adherence to standardized heart failure core measures: a performance evaluation study of 2958 patients. J Card Fail 2008;14: 95-102. (Pubitemid 351313960)
8. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007;167: 1493-502. (Pubitemid 47134697)
9. Werner RM, Bradlow ET. Relationship between Medicare's hospital compare performance measures and mortality rates. JAMA 2006; 296:2694-702. (Pubitemid 44920181)
10. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007;297:61-70. (Pubitemid 46041727)
11. Patterson ME, Hernandez AF, Hammill BG, et al. Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care 2010;48:210-6.
12. Ryan AM, Burgess Jr JF, Tompkins CP, et al. The relationship between Medicare's process of care quality measures and mortality: Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Inquiry 2009;46:274-90.
13. Heidenreich PA, Hernandez AF, Yancy CW, et al. Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. Circ Cardiovasc Qual Outcomes 2012;5:37-43.
14. Yancy CW, Wang TY, Ventura HO, et al. The coalition to reduce racial and ethnic disparities in cardiovascular disease outcomes (credo): why credo matters to cardiologists. J Am Coll Cardiol 2011; 57:245-52.
15. Joynt KE, Harris Y, Orav EJ, et al. Quality of care and patient outcomes in critical access rural hospitals. JAMA 2011;306:45-52.
16. Joynt KE, Orav EJ, Jha AK. The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure. Ann Intern Med 2011;154:94-102.
17. Philbin EF, Dec GW, Jenkins PL, et al. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol 2001;87:1367-71. (Pubitemid 32523020)
18. Joynt KE, Jha AK. Who has higher readmission rates for heart failure, and why? Implications for efforts to improve care using financial incentives. Circ Cardiovasc Qual Outcomes 2011;4:53-9.
19. Group TCTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
20. Investigators TS. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
21. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334: 1349-55. (Pubitemid 26152713)
22. Group M-HS. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
23. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6. (Pubitemid 37093917)
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
25. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.
26. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. (Pubitemid 40110811)
27. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
28. Jessup M, Abraham WT, Casey Jr DE. 2009 focused update: ACC/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;119:1977-2016.
29. Fonarow GC, Abraham WT, Albert NM, et al. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail 2007; 13:722-31. (Pubitemid 350080975)
30. McKalip D. Pay for performance and public reporting: risks to patients outweigh benefits. J Am Phys Surg 2009;14:113-7.
31. Hernandez AF, Fonarow GC, Liang L, et al. The need for multiple measures of hospital quality: results from the Get with the Guidelines- Heart Failure Registry of the American Heart Association. Circulation 2011;124:712-9.